collection
MENU ▼
Read by QxMD icon Read
search

Multiple myeloma

shared collection
15 papers 0 to 25 followers
By Yunquera Romero Residente farmacia hospitalaria
https://www.readbyqxmd.com/read/24974802/lenalidomide-in-relapsed-and-refractory-multiple-myeloma-disease-feasibility-and-benefits-of-long-term-treatment
#1
Manola Zago, Katharina Oehrlein, Corinna Rendl, Corinna Hahn-Ast, Lothar Kanz, Katja Weisel
Lenalidomide in combination with dexamethasone is an effective and well-established treatment of relapsed or refractory multiple myeloma (rrMM) disease. Due to the scarcity of reports assessing benefit and risk of long-term lenalidomide treatment in non-selected rrMM patients, we retrospectively analysed the long-term outcome in patients with rrMM treated with lenalidomide and dexamethasone. Sixty-seven patients (pts) who were treated with lenalidomide/dexamethasone for rrMM in the approved indication from 2007 to 2011 were included in this retrospective, single-centre analysis...
December 2014: Annals of Hematology
https://www.readbyqxmd.com/read/25170966/carfilzomib-in-multiple-myeloma
#2
REVIEW
Claudia Andreu-Vieyra, James R Berenson
INTRODUCTION: Advances in drug therapy for multiple myeloma (MM) during the previous decade have improved survival outcomes; however, the disease remains incurable as patients eventually relapse or become refractory to all available therapies. Therefore, there is a clear need for more effective and well-tolerated treatments. AREAS COVERED: We review preclinical and clinical data regarding the use of carfilzomib , a proteasome inhibitor that is structurally and mechanistically distinct from bortezomib, for the treatment of MM patients...
November 2014: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/24941833/-safety-and-efficacy-of-subcutaneous-administration-of-bortezomib-in-the-treatment-of-multiple-myeloma
#3
Yan-sheng Wang, Shi-hua Ding, Fan Wu, Zhi-tao Wang, Qiang-sheng Wang
OBJECTIVE: To analyze the efficacy and safety of subcutaneous administration of bortezomib in the treatment of multiple myeloma (MM) patients. METHODS: A total of 26 MM patients were enrolled in this study and treated with BDT (bortezomib-dexamethasone-thalidomide). In the 26 MM patients, 12 patients received subcutaneous administration of Bortezomib while 14 patients received conventional intravenous administration. The outcomes and adverse effects of two groups were retrospectively evaluated and compared...
May 2014: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
https://www.readbyqxmd.com/read/22023551/low-dose-vs-high-dose-thalidomide-for-advanced-multiple-myeloma-a-prospective-trial-from-the-intergroupe-francophone-du-my%C3%A3-lome
#4
RANDOMIZED CONTROLLED TRIAL
Ibrahim Yakoub-Agha, Jean-Yves Mary, Cyrille Hulin, Chantal Doyen, Gérald Marit, Lotfi Benboubker, Laurent Voillat, Philippe Moreau, Christian Berthou, Anne-Marie Stoppa, Frédéric Maloisel, Philippe Rodon, Mamoun Dib, Brigitte Pegourie, Philippe Casassus, Borhane Slama, Ghandi Damaj, Robert Zerbib, Jean-Luc Harousseau, Mohamad Mohty, Thierry Facon
This multicentre prospective randomised trial compared the efficacy and safety of two doses of thalidomide in patients with relapsed or refractory myeloma. The study was designed to test the non-inferior efficacy and to confirm the better tolerability of low-dose thalidomide as compared to a higher dose. Four hundred patients were randomly assigned to receive either 100 or 400 mg/day of thalidomide. Dexamethasone treatment was added in both arms for patients with stable disease or treatment failure at 12 weeks...
March 2012: European Journal of Haematology
https://www.readbyqxmd.com/read/23025991/predictive-factors-of-survival-after-thalidomide-therapy-in-advanced-multiple-myeloma-long-term-follow-up-of-a-prospective-multicenter-nonrandomized-phase-ii-study-in-120-patients
#5
MULTICENTER STUDY
Olivier Decaux, Alain Renault, Véronique Sébille, Philippe Moreau, Michel Attal, Laurent Voillat, Brigitte Pegourie, Mourad Tiab, Thierry Facon, Robert Zerbib, Bernard Grosbois, Eric Bellissant
UNLABELLED: Thalidomide monotherapy has demonstrated consistent results in the treatment of advanced multiple myeloma. We report a 9-year follow-up of a French multicenter nonrandomized phase II study that evaluated the effect of oral thalidomide in 120 patients with advanced multiple myeloma. Independent predictors of survival were response to last therapy, performance status, serum β(2)-microglobulin level, platelet count, and response at day 60 of treatment. BACKGROUND: Thalidomide monotherapy has demonstrated consistent results in the treatment of advanced multiple myeloma...
December 2012: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/21849487/bortezomib-plus-dexamethasone-versus-reduced-dose-bortezomib-thalidomide-plus-dexamethasone-as-induction-treatment-before-autologous-stem-cell-transplantation-in-newly-diagnosed-multiple-myeloma
#6
RANDOMIZED CONTROLLED TRIAL
Philippe Moreau, Herve Avet-Loiseau, Thierry Facon, Michel Attal, Mourad Tiab, Cyrille Hulin, Chantal Doyen, Laurent Garderet, Edouard Randriamalala, Carla Araujo, Gérard Lepeu, Gerald Marit, Denis Caillot, Martine Escoffre, Bruno Lioure, Lotfi Benboubker, Brigitte Pégourié, Brigitte Kolb, Anne Marie Stoppa, Jean-Gabriel Fuzibet, Olivier Decaux, Mamoun Dib, Christian Berthou, Carine Chaleteix, Catherine Sebban, Catherine Traullé, Jean Fontan, Marc Wetterwald, Pascal Lenain, Claire Mathiot, Jean-Luc Harousseau
The Intergroupe Francophone du Myelome conducted a randomized trial to compare bortezomib-dexamethasone (VD) as induction before high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to a combination consisting of reduced doses of bortezomib and thalidomide plus dexamethasone (vtD) in patients with multiple myeloma. Overall, a total of 199 patients were centrally randomly assigned to receive VD or vtD. After 4 cycles, the complete response (CR) rate was the same in both groups (13% in the vtD arm, 12% in the VD arm, P = ...
November 24, 2011: Blood
https://www.readbyqxmd.com/read/24888806/combination-of-international-scoring-system-3-high-lactate-dehydrogenase-and-t-4-14-and-or-del-17p-identifies-patients-with-multiple-myeloma-mm-treated-with-front-line-autologous-stem-cell-transplantation-at-high-risk-of-early-mm-progression-related-death
#7
Philippe Moreau, Michele Cavo, Pieter Sonneveld, Laura Rosinol, Michel Attal, Annalisa Pezzi, Hartmut Goldschmidt, Juan Jose Lahuerta, Gerald Marit, Antonio Palumbo, Bronno van der Holt, Joan Bladé, Maria Teresa Petrucci, Kai Neben, Jesus san Miguel, Francesca Patriarca, Henk Lokhorst, Elena Zamagni, Cyrille Hulin, Norma Gutierrez, Thierry Facon, Denis Caillot, Lotfi Benboubker, Jean-Luc Harousseau, Xavier Leleu, Hervé Avet-Loiseau, Jean-Yves Mary
PURPOSE: To construct and validate among patients with multiple myeloma (MM) who were treated with intensive therapy a prognostic index of early MM progression-related death. PATIENTS AND METHODS: Patient-level data from the Intergroupe Francophone du Myélome (IFM) 2005-01 trial (N = 482) were used to construct the prognostic index. The event was MM progression-related death within 2 years from treatment initiation. The index was validated using data from three other trials: the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) 26866138-MMY-3006 trial (N = 480), the Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA)-GEMMENOS65 trial (N = 390), and the Hemato-Oncologie voor Volwassenen Nederland (HOVON) -65/German-Speaking Myeloma Multicenter Group (GMMG) -HD4 trial (N = 827)...
July 10, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/23796999/chromosomal-abnormalities-are-major-prognostic-factors-in-elderly-patients-with-multiple-myeloma-the-intergroupe-francophone-du-my%C3%A3-lome-experience
#8
Hervé Avet-Loiseau, Cyrille Hulin, Loic Campion, Philippe Rodon, Gerald Marit, Michel Attal, Bruno Royer, Mamoun Dib, Laurent Voillat, Didier Bouscary, Denis Caillot, Marc Wetterwald, Brigitte Pegourie, Gerard Lepeu, Bernadette Corront, Lionel Karlin, Anne-Marie Stoppa, Jean-Gabriel Fuzibet, Xavier Delbrel, Francois Guilhot, Brigitte Kolb, Olivier Decaux, Thierry Lamy, Laurent Garderet, Olivier Allangba, Francois Lifermann, Bruno Anglaret, Philippe Moreau, Jean-Luc Harousseau, Thierry Facon
PURPOSE: Chromosomal abnormalities, especially t(4;14) and del(17p), are major prognostic factors in patients with multiple myeloma (MM). However, this has been especially demonstrated in patients age < 66 years treated with intensive approaches. The goal of this study was to address this issue in elderly patients treated with conventional-dose chemotherapy. PATIENTS AND METHODS: To answer this important question, we retrospectively analyzed a series of 1,890 patients (median age, 72 years; range, 66 to 94 years), including 1,095 with updated data on treatment modalities and survival...
August 1, 2013: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/20962323/translocation-t-14-16-and-multiple-myeloma-is-it-really-an-independent-prognostic-factor
#9
RANDOMIZED CONTROLLED TRIAL
Hervé Avet-Loiseau, Florent Malard, Loic Campion, Florence Magrangeas, Catherine Sebban, Bruno Lioure, Olivier Decaux, Thierry Lamy, Laurence Legros, Jean-Gabriel Fuzibet, Mauricette Michallet, Bernadette Corront, Pascal Lenain, Cyrille Hulin, Claire Mathiot, Michel Attal, Thierry Facon, Jean-Luc Harousseau, Stephane Minvielle, Philippe Moreau
Many trials in myeloma are stratified on cytogenetic abnormalities. Among them, the most commonly chosen are the t(4;14), the del(17p), and the t(14;16). If data are well established for t(4;14) and del(17p), very few data support the use of t(14;16). To address this issue, we retrospectively analyzed 1003 patients with newly diagnosed myeloma for this abnormality. We identified 32 patients with the t(14;16). Compared with patients lacking the t(14;16), we did not observe any difference in overall survival (P = ...
February 10, 2011: Blood
https://www.readbyqxmd.com/read/17614819/bortezomib-in-combination-with-intermediate-dose-dexamethasone-and-continuous-low-dose-oral-cyclophosphamide-for-relapsed-multiple-myeloma
#10
MULTICENTER STUDY
Martin Kropff, Guido Bisping, Elke Schuck, Peter Liebisch, Nicola Lang, Markus Hentrich, Tobias Dechow, Nicolaus Kröger, Hans Salwender, Bernd Metzner, Orhan Sezer, Monika Engelhardt, Hans-Heinrich Wolf, Hermann Einsele, Sarah Volpert, Achim Heinecke, Wolfgang E Berdel, Joachim Kienast
A phase 2 trial was performed to study the combination of bortezomib (VELCADE) with intermediate-dose dexamethasone (DEX), and continuous low-dose oral cyclophosphamide (CY) in patients with relapsed multiple myeloma (MM). Fifty-four patients with advanced MM were enroled to receive eight 3-week treatment cycles with bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11, followed by three 5-week cycles with bortezomib 1.3 mg/m(2) on days 1, 8, 15, and 22. Within all cycles, DEX 20 mg/d was given orally on the day of bortezomib injection and the day thereafter...
August 2007: British Journal of Haematology
https://www.readbyqxmd.com/read/23558525/consolidation-with-vtd-significantly-improves-the-complete-remission-rate-and-time-to-progression-following-vtd-induction-and-single-autologous-stem-cell-transplantation-in-multiple-myeloma
#11
MULTICENTER STUDY
X Leleu, G Fouquet, B Hebraud, M Roussel, D Caillot, M L Chrétien, B Arnulf, R Szalat, L Garderet, L Benajiba, B Pegourie, C Regny, B Royer, A Caulier, A M Stoppa, S Garciaz, C Touzeau, C Chaleteix, J P Fermand, H A Loiseau, T Facon, M Attal, P Moreau
No abstract text is available yet for this article.
November 2013: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/14695409/single-versus-double-autologous-stem-cell-transplantation-for-multiple-myeloma
#12
RANDOMIZED CONTROLLED TRIAL
Michel Attal, Jean-Luc Harousseau, Thierry Facon, François Guilhot, Chantal Doyen, Jean-Gabriel Fuzibet, Mathieu Monconduit, Cyrille Hulin, Denis Caillot, Reda Bouabdallah, Laurent Voillat, Jean-Jacques Sotto, Bernard Grosbois, Regis Bataille
BACKGROUND: We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS: At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS: A complete or a very good partial response was achieved by 42 percent of patients in the single-transplant group and 50 percent of patients in the double-transplant group (P=0...
December 25, 2003: New England Journal of Medicine
https://www.readbyqxmd.com/read/23319574/pomalidomide-plus-low-dose-dexamethasone-is-active-and-well-tolerated-in-bortezomib-and-lenalidomide-refractory-multiple-myeloma-intergroupe-francophone-du-my%C3%A3-lome-2009-02
#13
RANDOMIZED CONTROLLED TRIAL
Xavier Leleu, Michel Attal, Bertrand Arnulf, Philippe Moreau, Catherine Traulle, Gerald Marit, Claire Mathiot, Marie Odile Petillon, Margaret Macro, Murielle Roussel, Brigitte Pegourie, Brigitte Kolb, Anne Marie Stoppa, Bernadette Hennache, Sabine Bréchignac, Nathalie Meuleman, Beatrice Thielemans, Laurent Garderet, Bruno Royer, Cyrille Hulin, Lotfi Benboubker, Olivier Decaux, Martine Escoffre-Barbe, Mauricette Michallet, Denis Caillot, Jean Paul Fermand, Hervé Avet-Loiseau, Thierry Facon
The combination of pomalidomide and dexamethasone can be safely administered to patients with multiple myeloma (MM) and has significant efficacy, although the optimal regimen remains to be determined. Patients with MM whose disease progressed after multiple lines of therapy have limited treatment options. We designed a multicenter, phase 2 randomized study assessing two different dose regimens of pomalidomide and dexamethasone in advanced MM. Treatment response was assessed centrally. Pomalidomide (4 mg) was given orally on days 1 to 21 (arm 21/28) or continuously (arm 28/28) over a 28-day cycle, plus dexamethasone given weekly...
March 14, 2013: Blood
https://www.readbyqxmd.com/read/17920916/melphalan-and-prednisone-plus-thalidomide-versus-melphalan-and-prednisone-alone-or-reduced-intensity-autologous-stem-cell-transplantation-in-elderly-patients-with-multiple-myeloma-ifm-99-06-a-randomised-trial
#14
RANDOMIZED CONTROLLED TRIAL
Thierry Facon, Jean Yves Mary, Cyrille Hulin, Lotfi Benboubker, Michel Attal, Brigitte Pegourie, Marc Renaud, Jean Luc Harousseau, Gaëlle Guillerm, Carine Chaleteix, Mamoun Dib, Laurent Voillat, Hervé Maisonneuve, Jacques Troncy, Véronique Dorvaux, Mathieu Monconduit, Claude Martin, Philippe Casassus, Jérôme Jaubert, Henry Jardel, Chantal Doyen, Brigitte Kolb, Bruno Anglaret, Bernard Grosbois, Ibrahim Yakoub-Agha, Claire Mathiot, Hervé Avet-Loiseau
BACKGROUND: In multiple myeloma, combination chemotherapy with melphalan plus prednisone is still regarded as the standard of care in elderly patients. We assessed whether the addition of thalidomide to this combination, or reduced-intensity stem cell transplantation, would improve survival. METHODS: Between May 22, 2000, and Aug 8, 2005, 447 previously untreated patients with multiple myeloma, who were aged between 65 and 75 years, were randomly assigned to receive either melphalan and prednisone (MP; n=196), melphalan and prednisone plus thalidomide (MPT; n=125), or reduced-intensity stem cell transplantation using melphalan 100 mg/m2 (MEL100; n=126)...
October 6, 2007: Lancet
https://www.readbyqxmd.com/read/11806971/comparison-of-200-mg-m-2-melphalan-and-8-gy-total-body-irradiation-plus-140-mg-m-2-melphalan-as-conditioning-regimens-for-peripheral-blood-stem-cell-transplantation-in-patients-with-newly-diagnosed-multiple-myeloma-final-analysis-of-the-intergroupe-francophone
#15
RANDOMIZED CONTROLLED TRIAL
Philippe Moreau, Thierry Facon, Michel Attal, Cyrille Hulin, Mauricette Michallet, Frédéric Maloisel, Jean-Jacques Sotto, François Guilhot, Gérald Marit, Chantal Doyen, Jérôme Jaubert, Jean-Gabriel Fuzibet, Sylvie François, Lotfi Benboubker, Matthieu Monconduit, Laurent Voillat, Margaret Macro, Christian Berthou, Véronique Dorvaux, Bernard Pignon, Bernard Rio, Thomas Matthes, Philippe Casassus, Denis Caillot, Norbert Najman, Bernard Grosbois, Régis Bataille, Jean-Luc Harousseau
High-dose therapy has become a common treatment for myeloma. The objective of this study (Intergroupe Francophone du Myélome [IFM] 9502 trial) was to compare in a prospective and randomized trial the 2 most widely used conditioning regimens before autologous stem cell transplantation in newly diagnosed symptomatic patients younger than 65 years old: 8 Gy total body irradiation plus 140 mg/m(2) melphalan (arm A) versus 200 mg/m(2) melphalan (arm B). A total of 282 evaluable patients were compared--140 in arm A and 142 in arm B...
February 1, 2002: Blood
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"